VHT and XBI offer distinct risk-reward profiles, with VHT providing diversified healthcare sector stability and XBI serving as a high-beta, concentrated play on the biotechnology subsector.
VHT is highlighted for its broad healthcare coverage, low expense ratio, and stable income, but with lower recent returns than XBI.
XBI is noted for its targeted biotech exposure and higher volatility, with stronger recent returns but deeper drawdowns.
Eli Lilly is mentioned as one of VHT's largest holdings, without direct analysis.
Johnson & Johnson is mentioned as one of VHT's largest holdings, without direct analysis.
AbbVie is mentioned as one of VHT's largest holdings, without direct analysis.
Twist Bioscience is mentioned as one of XBI's largest holdings, without direct analysis.
Moderna is mentioned as one of XBI's largest holdings, without direct analysis.
Natera is mentioned as one of XBI's largest holdings, without direct analysis.
Investors weighing healthcare exposure must choose between the broad, low-cost Vanguard Health Care ETF (VHT) and the concentrated, high-volatility SPDR S&P Biotech ETF (XBI). While VHT offers stability and a 1.48% dividend yield, XBI has delivered superior one-year returns at the cost of significantly higher drawdowns.
VHT provides broad, passive exposure to the entire U.S. healthcare sector, while XBI focuses exclusively on the biotechnology industry with a more concentrated portfolio.